Quantcast
Last updated on April 17, 2014 at 1:21 EDT

Elsevier Launches Next Generation Codifa, Providing Italian Doctors with Real Time Access to Critical Drug Information

August 3, 2011

MILAN, August 3, 2011 /PRNewswire/ –

Codifa Enables Italian Professionals to Take Better Decisions

in a Shorter Time

Elsevier, the world-leading global provider of scientific, technical,
and medical information products and services, announced today a new release
of Codifa [http://www.codifa.it ] (http://www.codifa.it [
\\elsamsdatp01va\corpcoms\CorpRel\ExtComms\Press Releases\Press releases
2011\August\Draft\Elsevier Launches Next Generation Codifa, Providing
Italian Doctors with Real Time Access to Critical Drug
Information\www.codifa.it ]), an easy to use and powerful online point of
care drug information platform serving Italian healthcare providers.

“We are delighted to provide real time access to critical data on drugs,
tailored to a specific clinical setting and patient’s needs,” said Emile
Blomme, Managing Director, Elsevier Italy. “Codifa will greatly improve the
appropriateness of care, help reduce risk, optimize operating costs and
ultimately diminish malpractice liability.”

This project is part of Elsevier’s continuous efforts to offer most
qualified and relevant international contents to its local or multi-language
clinical products in Europe. Codifa’s critical drug information reduces the
clinical risk associated with errors in prescribing or administering drugs,
adverse reactions and suboptimal dosages.

The new Codifa system improves significantly the core functionalities
and contents of the 2005 release, providing a new user-friendly interface
and search engine designed to enhance and speed up information retrieval,
reading, integration in workflows and use on handheld devices. Longstanding
partnerships with important, Italian and international, institutions and
associations (both public and private) ensure that Codifa provides
authoritative, information on drug interactions, global brand name
conversion, generic drug search and price trends.

About Elsevier
Elsevier is a world-leading provider of scientific, technical and medical
information products and services. The company works in partnership with the
global science and health communities to publish more than 2,000 journals,
including The Lancet [http://www.thelancet.com ] and Cell
[http://www.cell.com ], and close to 20,000 book titles, including major
reference works from Mosby and Saunders. Elsevier’s online solutions include
SciVerse ScienceDirect [http://www.sciencedirect.com ], SciVerse Scopus
[http://www.scopus.com ], Reaxys [http://www.reaxys.com ], MD Consult
[http://www.mdconsult.com ] and Nursing Consult
[http://www.nursingconsult.com ], which enhance the productivity of science
and health professionals, and the SciVal suite [http://www.scival.com ] and
MEDai’s Pinpoint Review [http://www.medai.com ], which help research and
health care institutions deliver better outcomes more cost-effectively.

A global business headquartered in Amsterdam, Elsevier
[http://www.elsevier.com ] employs 7,000 people worldwide. The company is
part of Reed Elsevier Group PLC [http://www.reedelsevier.com ], a
world-leading publisher and information provider, which is jointly owned by
Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext
Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock
Exchange).

        Media contact
        Ludovico Baldessin
        Digital Business Solutions Director, Elsevier
        +39-02-88184-354
        l.baldessin@elsevier.com

SOURCE Elsevier


Source: newswire